Progyny (NASDAQ:PGNY) and American Renal Associates (NYSE:ARA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Valuation and Earnings
This table compares Progyny and American Renal Associates’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|American Renal Associates||$805.78 million||0.38||-$28.77 million||N/A||N/A|
Institutional and Insider Ownership
85.4% of American Renal Associates shares are owned by institutional investors. 9.4% of American Renal Associates shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings for Progyny and American Renal Associates, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|American Renal Associates||0||6||0||0||2.00|
Progyny presently has a consensus target price of $29.67, indicating a potential upside of 3.95%. American Renal Associates has a consensus target price of $10.33, indicating a potential upside of 10.75%. Given American Renal Associates’ higher probable upside, analysts plainly believe American Renal Associates is more favorable than Progyny.
This table compares Progyny and American Renal Associates’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|American Renal Associates||-1.75%||23.16%||2.04%|
American Renal Associates beats Progyny on 6 of the 11 factors compared between the two stocks.
Progyny Company Profile
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption expenses for clients and their employees. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.